Clinic Roundup

July 2010
BioWorld Today;7/20/2010, Vol. 21 Issue 138, p5
This section offers news briefs on clinical trials. Positive results were obtained by Aegera Therapeutics Inc. from the Phase I portion of its trial of AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma or primary liver cancer. The first participant was enrolled by CytRx Corp. in its Phase II trial examining bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia. The Indian Drugs Controller General has approved the Phase II trial of Alferon N Injection by Hemispherx Biopharma Inc.


Related Articles

  • IDI News Round-up.  // PharmaWatch: Monthly Review;Nov2007, Vol. 6 Issue 11, p15 

    The article provides updates on the development of treatments for immune disorders and inflammation. Critical Therapeutics Inc. has launched its inhalation product, Perforomist, as a treatment for chronic obstructive pulmonary disease (COPD). MediciNova Inc. has reported good results from its...

  • Brain Cancer Update.  // PharmaWatch: Cancer;Mar2006, Vol. 5 Issue 3, p4 

    The article reports on developments about drugs for treating brain cancer. CytRx Corp. has submitted a protocol to the U.S. Food and Drug Administration for the expansion of the clinical trial of arimoclomol for the treatment of amyotrophic lateral sclerosis. Schering-Plough Corp.'s Temodal...

  • Chronic tonic.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Announces a Phase III clinical study of Hemispherx Biopharma's clinical study of its drug Ampligen. Details on the placebo-controlled study; Results of earlier trial.

  • Hemispherx Down on Ampligen FDA Rejection.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p4 

    The article informs that the U.S. Food & Drug Administration (FDA) has rejected the chronic fatigue drug Ampligen manufactured by Hemispherx Biopharma Inc. It discusses the impact of the FDA's decision on the company. The shares of Hemispherx declined by 41 percent. The FDA wanted to have more...

  • Hemispherx, Emerge.  // Contract Pharma;Sep2015, Vol. 17 Issue 7, p152 

    The article reports that pharmaceutical companies Emerge Health Pty Ltd. and Hemispherx Biopharma Inc. have collaborated to seek approval of Alferon N Injection from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) and the Australia Therapeutic Goods Administration (TGA).

  • International models of investigator-initiated trials: implications for Japan. Trimble, E. L.; Ledermann, J.; Law, K.; Miyata, T.; Imamura, C. K.; Nam, B.-H.; Kim, Y.H.; Bang, Y.-J.; Michaels, M.; Ardron, D.; Amano, S.; Ando, Y.; Tominaga, T.; Kurokawa, K.; Takebe, N. // Annals of Oncology;Dec2012, Vol. 23 Issue 12, p3151 

    Background Academic/institutional investigator-initiated clinical trials benefit individuals and society by supplementing gaps in industry-sponsored clinical trials. Materials In May 2010, experts from Japan, the Republic of Korea, the UK, and the United States, met at a symposium in Tokyo,...

  • Maxim: melanoma disappointment dents Ceplene hopes.  // PharmaWatch: Monthly Review;December2004, Vol. 3 Issue 12, p6 

    Reports on the intention of Maxim Pharmaceuticals Inc. to withdraw its new drug application for the Ceplene drug in combination with interleukin-2 for the treatment of advanced malignant melanoma. Results of the confirmatory phase III trial for the drug; Reduction in the commercial potential of...

  • Hemispherx Biopharma acquires global rights to Alferon N.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p21 

    Focuses on the acquisition of all the worldwide rights to Alferon N by Hemispherx Biopharma and U.S. Food and Drug Administration approved biological production facility located in New Brunswick, New Jersey from Interferon Sciences Inc. Area of the production facility; Benefits of the...

  • After Stock Bump, Hemispherx Bringing in $18.3M Publicly. Boggs, Jennifer // BioWorld Today;5/12/2009, Vol. 20 Issue 90, p3 

    The article reports on the decision of Hemispherx Biopharma Inc. to raise $18.3 million in public equity offerings in May 2009. The company agreed to sell common shares priced at $1.10 each to bring in $15 million, along with Series A warrants to purchase 6,136,364 shares of common stock. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics